Ovid Therapeutics Inc (OVID)
NASDAQ:OVID
OVID Stock Chart & Stats
$2.30
-$0.03(-2.93%)
At close: 4:00 PM EST
$2.30
-$0.03(-2.93%)
Day’s Range― - ―
52-Week Range$0.24 - $2.72
Previous CloseN/A
Volume22.63K
Average Volume (3M)3.47M
Market Cap
$303.31M
Enterprise Value$347.63M
Total Cash (Recent Filing)$90.45M
Total Debt (Recent Filing)$13.42M
Price to Earnings (P/E)―
Beta2.04
Next Earnings
May 13, 2026EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.06
Shares Outstanding131,874,630
10 Day Avg. Volume7,061,833
30 Day Avg. Volume3,472,304
Financial Highlights & Ratios
PEG Ratio0.20
Price to Book (P/B)0.92
Price to Sales (P/S)16.57
P/FCF Ratio-3.14
Enterprise Value/Market Cap1.15
Enterprise Value/Revenue47.94
Enterprise Value/Gross Profit50.00
Enterprise Value/Ebitda-8.31
Forecast
1Y Price Target
$4.72Price Target Upside105.22% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-0.5
Revenue Forecast (FY)$166.86K
Bulls Say, Bears Say
Bulls Say
Ophthalmic SafetyComprehensive ophthalmic testing detected no retinal changes, supporting a differentiated safety profile versus earlier GABA‑AT inhibitors and reducing concerns about vision risk.
Pharmacology And BiomarkersStrong on‑target biomarker responses, including cortical inhibition and increased GABA levels at low doses, suggest potential therapeutic effect with a safer dosing window than first‑generation drugs.
Rare-disease ExpansionPlanned development in tuberous sclerosis complex and infantile spasms targets severe unmet needs and could enable premium pricing and a broader commercial opportunity despite small patient populations.
Bears Say
Early-stage Clinical RiskA portfolio that is early in clinical development increases uncertainty about eventual clinical success and commercial outcomes for lead programs.
Financing DependenceOngoing development depends on completing financing and potential warrant exercises, creating reliance on external capital that could dilute shareholders or delay programs.
Regulatory UncertaintyPersistent regulatory uncertainty over class ocular toxicity warnings means approval could require robust, specific long‑term safety data to overturn historical concerns.
Ovid Therapeutics News
OVID FAQ
What was Ovid Therapeutics Inc’s price range in the past 12 months?
Ovid Therapeutics Inc lowest stock price was $0.24 and its highest was $2.72 in the past 12 months.
What is Ovid Therapeutics Inc’s market cap?
Ovid Therapeutics Inc’s market cap is $303.31M.
When is Ovid Therapeutics Inc’s upcoming earnings report date?
Ovid Therapeutics Inc’s upcoming earnings report date is May 13, 2026 which is in 44 days.
How were Ovid Therapeutics Inc’s earnings last quarter?
Ovid Therapeutics Inc released its earnings results on Mar 18, 2026. The company reported $0.06 earnings per share for the quarter, beating the consensus estimate of -$0.117 by $0.177.
Is Ovid Therapeutics Inc overvalued?
According to Wall Street analysts Ovid Therapeutics Inc’s price is currently Undervalued.
Does Ovid Therapeutics Inc pay dividends?
Ovid Therapeutics Inc does not currently pay dividends.
What is Ovid Therapeutics Inc’s EPS estimate?
Ovid Therapeutics Inc’s EPS estimate is -0.12.
How many shares outstanding does Ovid Therapeutics Inc have?
Ovid Therapeutics Inc has 131,874,630 shares outstanding.
What happened to Ovid Therapeutics Inc’s price movement after its last earnings report?
Ovid Therapeutics Inc reported an EPS of $0.06 in its last earnings report, beating expectations of -$0.117. Following the earnings report the stock price went up 14.428%.
Which hedge fund is a major shareholder of Ovid Therapeutics Inc?
Currently, no hedge funds are holding shares in OVID
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Ovid Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.72 (105.22% Upside)
$4.72 (105.22% Upside)
Blogger Sentiment
Bullish
OVID Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 9.4M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 0.1%
Last 30 Days ▲ 2.5%
Last 30 Days ▲ 2.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
508.46%
12-Months-Change
Fundamentals
Return on Equity
-23.98%
Trailing 12-Months
Asset Growth
63.76%
Trailing 12-Months
Company Description
Ovid Therapeutics Inc
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies. It also develops OV882, a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815 for the treatment of kinesin-family of proteins associated neurological disorder. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
OVID Company Deck
OVID Earnings Call
Q4 2026
0:00 / 0:00
OVID Stock 12 Month Forecast
Average Price Target
$4.72
▲(105.22% Upside)
Technical Analysis
Opus Genetics
―
Zentalis Pharmaceuticals
―
Inhibikase Therapeutics
―
Surrozen
―
Biomea Fusion
―
Ownership Overview
9.79% Insiders
9.21% Mutual Funds
29.56% Other Institutional Investors
49.23% Public Companies and Individual Investors